Design and development of 5-HT7 receptor agonists

5-HT7受体激动剂的设计与开发

• 批准号: 8414200
• 负责人: Mikhail L Bondarev
• 金额: $ 10.53万
• 依托单位: HAMPTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-05 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8414200
• 关键词: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Receptor; Affinity; Aging; Agonist; Alzheimer' s Disease; Area; Attenuated; Binding; Binding Sites; Brain region; Chromans; Cognitive; Complex; Data; Development; Elements; Etiology; Goals; HTR2A gene; Hippocampal Formation; Hippocampus (Brain); Learning; Ligands; Measures; Memory; Memory Disorders; Memory impairment; Messenger RNA; Mission; Molecular Conformation; National Institute of General Medical Sciences; Nature; Pathway interactions; Pattern; Play; Positioning Attribute; Process; Radial; Research; Role; Senile Plaques; Series; Side; Structure; Structure-Activity Relationship; Testing; Therapeutic; Work; age related; analog; arm; base; density; design; ethylamine; frontal lobe; interest; mRNA Expression; memory process; prevent; pyridine; receptor; receptor binding; receptor expression; serotonin 7 receptor

DESCRIPTION (provided by applicant): Interest in 5-HT7 receptors derives mainly from the possibility that they can play a relevant role in normal or impaired memory. Numerous studies have found evidence of the presence of 5-HT7 receptors in cognitive pathways within hippocampal formation (HF) and the frontal cortex. It is known that 5-HT7 receptors appear to decline in the raphe complex during aging or Alzheimer's disease (AD). The evidence for the involvement of 5-HT7 receptors in mnemonic mechanisms was also confirmed by findings showing that the potential selective 5-HT7 receptor agonist AS 19 enhanced memory consolidation, attenuated mRNA receptors expression, and the facilitatory memory effect was reversed by SB-269970 (5-HT7 receptor antagonist). Understanding the role of 5-HT7 receptors in cognitive processes, including learning and memory, is limited by the lack of highly selective agonists. The central hypothesis of the proposed project is that the agonist ligands of arylpiperazine, thiopyridine and 2-anilinoimidazoline analogs bind in a similar manner upon interaction with 5-HT7 receptors and utilize some common ethylamine side-chain conformation required for agonist activity at the receptor. The major goal of the proposed research is to exploit a series of conformationally restricted pyridine and thiopyridine analogs, and to use them as templates for the design and development of potent and highly selective 5-HT7 receptor agonists. These templates are derived from a comparable analysis of four major classes of selective and nonselective 5-HT7 receptor agonists: arylpiperazines, aminotetralins/chromans, thiopyridines, and 2-anilinoimidazolines. The nature and position of substituents in the proposed templates can also provide us with a diversity of new 5-HT7 receptor agonists. The specific aims of this application are as follows: (i) prepare a series of conformationally restricted pyridie and thiopyridine analogs as potential agonists based on the templates containing common structural elements; (ii) determine their binding profile initially at 5-HT7 receptors and then stuy their affinity at 5-HT1A, 5-HT2A, D2L, ¿1, and ¿2 adrenoceptors to determine selectivity; (iii) determine the intrinsic activity of the proposed structures at 5-HT7 receptors, except for those that will have no affinity at 5-HT7 receptors; (iv) utilize the proposed templates and obtained pharmacological results to identify key structural elements essential for selectivity and agonist activity for 5-HT7 receptors. The findings of the proposed studies will serve as preliminary data for a further long-term project. The aim of the project will include: (i) development of the structure-affinity relationships (SAFIR) and structure-activity relationships (SAR) of the 5-HT7 receptor agonists, (ii) clarification of the function of 5-HT7 receptors and their agonists in the etiology of memory disorders, and (iii) design and development of potent agents that may find therapeutic application for the treatment of dysfunctional memory in aged-related decline and AD.

描述（由申请人提供）：对5-HT 7受体的兴趣主要来自它们在正常或受损记忆中发挥相关作用的可能性。许多研究已经发现海马结构（HF）和额叶皮质内的认知通路中存在5-HT 7受体的证据。已知在衰老或阿尔茨海默病（AD）期间，中缝复合体中的5-HT 7受体似乎下降。5-HT 7受体参与记忆机制的证据也被以下发现所证实：潜在的选择性5-HT 7受体激动剂AS 19增强记忆巩固，减弱mRNA受体表达，SB-269970（5-HT 7受体拮抗剂）逆转了易化记忆效应。了解5-HT 7受体在认知过程中的作用，包括学习和记忆，由于缺乏高选择性激动剂而受到限制。所提出的项目的中心假设是芳基哌嗪、硫代吡啶和2-苯胺基咪唑啉类似物的激动剂配体在与5-HT 7受体相互作用后以类似的方式结合，并利用受体激动剂活性所需的一些常见乙胺侧链构象。该研究的主要目标是开发一系列构象受限的吡啶和硫代吡啶类似物，并将其用作设计和开发有效和高选择性5-HT 7受体激动剂的模板。这些模板是从四个主要类别的选择性和非选择性5-HT 7受体激动剂：芳基哌嗪，氨基四氢萘/色满，硫代吡啶，和2-苯胺基咪唑啉的可比分析。所提出的模板中取代基的性质和位置也可以为我们提供多种新的5-HT 7受体激动剂。本申请的具体目的如下：（i）基于含有共同结构元件的模板制备一系列构象受限的吡啶和硫代吡啶类似物作为潜在的激动剂;（ii）首先确定它们在5-HT 7受体上的结合概况，然后研究它们在5-HT 1A、5-HT 2A、D2 L、<$1和<$2肾上腺素受体上的亲和力以确定选择性;（iii）确定所提出的结构对5-HT 7受体的内在活性，除了对5-HT 7受体没有亲和力的那些;（iv）利用所提出的模板和获得的药理学结果来鉴定对5-HT 7受体的选择性和激动剂活性至关重要的关键结构元件。拟议研究的结果将作为进一步长期项目的初步数据。该项目的目标将包括：（i）开发5-HT 7受体激动剂的结构-亲和力关系（SAFIR）和结构-活性关系（SAR），（ii）阐明5-HT 7受体及其激动剂在记忆障碍病因学中的功能，和（iii）设计和开发可用于治疗年龄相关衰退和AD中的功能障碍性记忆的有效药剂。